Development of a Nomogram Model for Treatment of Elderly Patients with Locoregionally Advanced Nasopharyngeal Carcinoma

被引:7
|
作者
Kou, Jia [1 ]
Zhang, Lu-Lu [2 ]
Yang, Xing-Li [1 ]
Wen, Dan-Wan [1 ]
Zhou, Guan-Qun [1 ]
Wu, Chen-Fei [1 ]
Xu, Si-Si [1 ]
Zheng, Wei-Hong [1 ]
Qi, Zhen-Yu [1 ]
Sun, Ying [1 ]
Lin, Li [1 ]
机构
[1] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Guangdong Key Lab Nasopharyngeal Carcinoma Diag &, Dept Radiat Oncol,Canc Ctr,State Key Lab Oncol So, Guangzhou 510060, Peoples R China
[2] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Guangdong Key Lab Nasopharyngeal Carcinoma Diag &, Dept Mol Diagnost,Canc Ctr,State Key Lab Oncol So, Guangzhou 510060, Peoples R China
来源
JOURNAL OF PERSONALIZED MEDICINE | 2021年 / 11卷 / 11期
基金
中国国家自然科学基金;
关键词
nasopharyngeal carcinoma; elderly patients; comorbidities; chemotherapy; INTENSITY-MODULATED RADIOTHERAPY; SQUAMOUS-CELL CARCINOMA; BARR-VIRUS DNA; CONCURRENT CHEMORADIOTHERAPY; SURVIVAL OUTCOMES; OLDER PATIENTS; PHASE-III; CHEMOTHERAPY; COMORBIDITY; MULTICENTER;
D O I
10.3390/jpm11111065
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
(1) Purpose: This study aims to explore risk-adapted treatment for elderly patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC) according to their pretreatment risk stratification and the degree of comorbidity. (2) Methods: A total of 583 elderly LA-NPC patients diagnosed from January 2011 to January 2018 are retrospectively studied. A nomogram for disease-free survival (DFS) is constructed based on multivariate Cox regression analysis. The performance of the model is evaluated by using the area under the curve (AUC) of the receiver operating characteristic curve and Harrell concordance index (C-index). Then, the entire cohort is divided into different risk groups according to the nomogram cutoff value determined by X-tile analysis. The degree of comorbidities is assessed by the Charlson Comorbidity Index (CCI). Finally, survival rates are estimated and compared by the Kaplan-Meier method and the log-rank test. (3) Results: A nomogram for DFS is constructed with T/N classification, Epstein-Barr virus DNA and albumin. The nomogram shows well prognostic performance and significantly outperformed the tumor-node-metastasis staging system for estimating DFS (AUC, 0.710 vs. 0.607; C-index, 0.668 vs. 0.585; both p < 0.001). The high-risk group generated by nomogram has significantly poorer survival compared with the low-risk group (3-year DFS, 76.7% vs. 44.6%, p < 0.001). For high-risk patients with fewer comorbidities (CCI = 2), chemotherapy combined with radiotherapy is associated with significantly better survival (p < 0.05) than radiotherapy alone. (4) Conclusion: A prognostic nomogram for DFS is constructed with generating two risk groups. Combining risk stratification and the degree of comorbidities can guide risk-adapted treatment for elderly LA-NPC patients.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] CT-Based Radiomics Nomogram for Prediction of Progression-Free Survival in Locoregionally Advanced Nasopharyngeal Carcinoma
    Yan, Chang
    Shen, De-Song
    Chen, Xiao-Bo
    Su, Dan-Ke
    Liang, Zhong-Guo
    Chen, Kai-Hua
    Li, Ling
    Liang, Xia
    Liao, Hai
    Zhu, Xiao-Dong
    [J]. CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 6911 - 6923
  • [32] A Phase II Study Of Concurrent Nimotuzumab And Intensity-Modulated Radiotherapy In Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
    Feng, Y.
    Cao, C.
    Jiang, F.
    Jin, Q.
    Jin, T.
    Huang, S.
    Hu, Q.
    Chen, Y.
    Piao, Y.
    Hua, Y.
    Feng, X.
    Chen, X.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E789 - E790
  • [33] Phase I clinical trial of nasopharyngeal radiotherapy and concurrent celecoxib for patients with locoregionally advanced nasopharyngeal carcinoma
    Xue, Wei-Ping
    Bai, Shou-Ming
    Luo, Ming
    Bi, Zhuo-Fei
    Liu, Yi-Ming
    Wu, Shao-Kun
    [J]. ORAL ONCOLOGY, 2011, 47 (08) : 753 - 757
  • [34] Toxicity of concurrent chemoradiotherapy with cetuximab for locoregionally advanced nasopharyngeal carcinoma
    Feng, Hui-Xia
    Guo, Su-Ping
    Li, Gui-Rong
    Zhong, Wen-Huan
    Chen, Liu
    Huang, Li-Ru
    Qin, Hui-Ying
    [J]. MEDICAL ONCOLOGY, 2014, 31 (09) : 1 - 6
  • [35] The next decade of clinical trials in locoregionally advanced nasopharyngeal carcinoma
    Peng, Liang
    Liu, Jin-Qi
    Chen, Yu-Pei
    Ma, Jun
    [J]. BRITISH JOURNAL OF RADIOLOGY, 2019, 92 (1102):
  • [36] Adjuvant metronomic chemotherapy for locoregionally advanced nasopharyngeal carcinoma Comment
    Kerbel, Robert S.
    Andre, Nicolas
    [J]. LANCET, 2021, 398 (10297): : 278 - 279
  • [37] Chemotherapy for locoregionally advanced nasopharyngeal carcinoma: Who really needs it
    Qu, Weiling
    Wang, Xuan
    Qiao, Qiao
    Wang, Yanli
    [J]. CANCER MEDICINE, 2023, 12 (06): : 6994 - 7004
  • [38] Toxicity of concurrent chemoradiotherapy with cetuximab for locoregionally advanced nasopharyngeal carcinoma
    Hui-Xia Feng
    Su-Ping Guo
    Gui-Rong Li
    Wen-Huan Zhong
    Liu Chen
    Li-Ru Huang
    Hui-Ying Qin
    [J]. Medical Oncology, 2014, 31
  • [39] Sequential chemoradiotherapy with gemcitabine and cisplatin for locoregionally advanced nasopharyngeal carcinoma
    Gu, Mo-Fa
    Liu, Li-Zhi
    He, Long-Jun
    Yuan, Wen-Xin
    Zhang, Rong
    Luo, Guang-Yu
    Xu, Guo-Liang
    Zhang, Hua-Man
    Yan, Chao-Xian
    Li, Jian-Jun
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2013, 132 (01) : 215 - 223
  • [40] Implication of comorbidity on the initiation of chemotherapy and survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma
    Guo, Rui
    Mao, Yan-Ping
    Chen, Lei
    Tang, Ling-Long
    Zhou, Guan-Qun
    Liu, Li-Zhi
    Tian, Li
    Zeng, Mu-Sheng
    Jia, Wei-Hua
    Shao, Jian-Yong
    Lin, Ai-Hua
    Ma, Jun
    [J]. ONCOTARGET, 2017, 8 (06) : 10594 - 10601